Antiretroviral Therapy for the Prevention of HIV-1 Transmission.

PubWeight™: 3.71‹?› | Rank: Top 1%

🔗 View Article (PMID 27424812)

Published in N Engl J Med on July 18, 2016

Authors

Myron S Cohen1, Ying Q Chen1, Marybeth McCauley1, Theresa Gamble1, Mina C Hosseinipour1, Nagalingeswaran Kumarasamy1, James G Hakim1, Johnstone Kumwenda1, Beatriz Grinsztejn1, Jose H S Pilotto1, Sheela V Godbole1, Suwat Chariyalertsak1, Breno R Santos1, Kenneth H Mayer1, Irving F Hoffman1, Susan H Eshleman1, Estelle Piwowar-Manning1, Leslie Cottle1, Xinyi C Zhang1, Joseph Makhema1, Lisa A Mills1, Ravindre Panchia1, Sharlaa Faesen1, Joseph Eron1, Joel Gallant1, Diane Havlir1, Susan Swindells1, Vanessa Elharrar1, David Burns1, Taha E Taha1, Karin Nielsen-Saines1, David D Celentano1, Max Essex1, Sarah E Hudelson1, Andrew D Redd1, Thomas R Fleming1, HPTN 052 Study Team

Author Affiliations

1: From the Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., M.C.H., I.F.H., J.E.); the Divisions of Vaccine and Infectious Disease (Y.Q.C., X.C.Z.) and Public Health Science (Y.Q.C.) and the Statistical Center for HIV/AIDS Research and Prevention (L.C.), Fred Hutchinson Cancer Research Center, and the Department of Biostatistics, University of Washington (T.R.F.) - both in Seattle; FHI 360, Washington, DC (M.M.), and Durham, NC (T.G.); Y.R. Gaitonde Center for AIDS Research and Education, Chennai (N.K.), and National AIDS Research Institute, Pune (S.V.G.) - both in India; University of Zimbabwe, Harare (J.G.H.); College of Medicine-Johns Hopkins Project, Blantyre, Malawi (J.K.); Instituto de Pesquisa Clinica Evandro Chagas (B.G.) and Hospital Geral de Nova Iguacu and Laboratorio de AIDS e Imunologia Molecular-IOC/Fiocruz (J.H.S.P.), Rio de Janeiro, and Servico de Infectologia, Hospital Nossa Senhora da Conceicao/GHC, Porto Alegre (B.R.S.) - both in Brazil; Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand (S.C.); Fenway Institute (K.H.M.) and Harvard School of Public Health (M.E.) - both in Boston; the Departments of Pathology (S.H.E., E.P.-M., S.E.H.) and Medicine (A.D.R.), Johns Hopkins University School of Medicine, the Department of Epidemiology, Bloomberg School of Public Health (T.E.T.), and Johns Hopkins Bloomberg School of Public Health (D.D.C.), Baltimore, and the Division of AIDS (V.E., D.B.) and Laboratory of Immunoregulation (A.D.R.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda - both in Maryland; Botswana Harvard AIDS Institute, Gaborone (J.M.); Centers for Disease Control and Prevention (CDC) Division of HIV/AIDS Prevention/KEMRI-CDC Research and Public Health Collaboration HIV Research Branch, Kisumu, Kenya (L.A.M.); Perinatal HIV Research Unit (R.P.) and Clinical HIV Research Unit, Department of Medicine, Faculty of Health Scien

Associated clinical trials:

Preventing Sexual Transmission of HIV With Anti-HIV Drugs | NCT00074581

Same-day Antiretroviral Therapy With BIC/F/TAF | NCT04712058

Ending the HIV Epidemic Through Point-of-Care Technologies (EHPOC) (EHPOC) | NCT04793750

Articles citing this

Combination antiretroviral therapy and cancer risk. Curr Opin HIV AIDS (2017) 0.80

Using Population-Size Estimation and Cross-sectional Survey Methods to Evaluate HIV Service Coverage Among Key Populations in Burkina Faso and Togo. Public Health Rep (2016) 0.80

Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing Agents. J Infect Dis (2017) 0.79

The Metropolitan Atlanta community adolescent rapid testing initiative study: closing the gaps in HIV care among youth in Atlanta, Georgia, USA. AIDS (2017) 0.79

Men living with HIV in serodiscordant relationships who desire a child/children. J Int AIDS Soc (2017) 0.78

Seek, test, treat: substance-using women in the HIV treatment cascade in South Africa. Addict Sci Clin Pract (2017) 0.78

Virologic outcomes in early antiretroviral treatment: HPTN 052. HIV Clin Trials (2017) 0.77

Polyvalent vaccine approaches to combat HIV-1 diversity. Immunol Rev (2017) 0.77

Phased implementation of spaced clinic visits for stable HIV-positive patients in Rwanda to support Treat All. J Int AIDS Soc (2017) 0.76

HIV care in Yangon, Myanmar; successes, challenges and implications for policy. AIDS Res Ther (2017) 0.75

Association between engagement in-care and mortality in HIV-positive persons: a cohort study. AIDS (2017) 0.75

Ending AIDS: The 90-90-90 strategy. Med J Armed Forces India (2017) 0.75

A longitudinal cohort study of HIV 'treatment as prevention' in gay, bisexual and other men who have sex with men: the Treatment with Antiretrovirals and their Impact on Positive And Negative men (TAIPAN) study protocol. BMC Infect Dis (2016) 0.75

HIV Futures 8: Protocol for a Repeated Cross-sectional and Longitudinal Survey of People Living with HIV in Australia. Front Public Health (2017) 0.75

Factors associated with pre-treatment HIV RNA: application for the use of abacavir and rilpivirine as the first-line regimen for HIV-infected patients in resource-limited settings. AIDS Res Ther (2017) 0.75

The Risk of Sexually Transmitted Infection and Its Influence on Condom Use among Pregnant Women in the Kintampo North Municipality of Ghana. J Sex Transm Dis (2017) 0.75

Highlights of the International Congress on Drug Therapy in HIV Infection, 23-26 October 2016, Glasgow, UK. J Virus Erad (2017) 0.75

Infection: Prophylactic ART in HIV serodiscordant couples. Nat Rev Urol (2016) 0.75

Differentiated HIV Rna Viral Load Monitoring in Resource Limited Settings: An Economic Analysis. Clin Infect Dis (2017) 0.75

The potential impact and cost of focusing HIV prevention on young women and men: A modeling analysis in western Kenya. PLoS One (2017) 0.75

Risk Factor Associated with Negative Spouse HIV Seroconversion among Sero-Different Couples: A Nested Case-Control Retrospective Survey Study in 30 Counties in Rural China. PLoS One (2016) 0.75

The Human Immunodeficiency Virus Endemic: Maintaining Disease Transmission in At-Risk Urban Areas. Sex Transm Dis (2017) 0.75

"Since both of us are using antiretrovirals, we have been supportive to each other": facilitators and barriers of pre-exposure prophylaxis use in heterosexual HIV serodiscordant couples in Kisumu, Kenya. J Int AIDS Soc (2016) 0.75

HIV-affected couples and individuals who desire children should be offered options for safer conception. J Int AIDS Soc (2017) 0.75

A Randomized-Controlled Trial of Computer-based Prevention Counseling for HIV-Positive Persons (HPTN 065). J AIDS Clin Res (2017) 0.75

Top Questions in ID: Pre-exposure Prophylaxis for HIV. Open Forum Infect Dis (2017) 0.75

Trends and outcomes of late initiation of combination antiretroviral therapy driven by late presentation among HIV-positive Taiwanese patients in the era of treatment scale-up. PLoS One (2017) 0.75

Towards standardized definitions for monitoring the continuum of HIV care in Europe. AIDS (2017) 0.75

Trends in ART Prescription and Viral Suppression Among HIV-Positive Young Adults in Care in the United States, 2009-2013. J Acquir Immune Defic Syndr (2017) 0.75

The global HIV epidemic: What the pathologist needs to know. Semin Diagn Pathol (2017) 0.75

Pre-exposure prophylaxis prescribing and retention in care among heterosexual women at a community-based comprehensive sexual health clinic. AIDS Care (2017) 0.75

Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052. PLoS One (2017) 0.75

Longitudinal Viral Suppression Among a Cohort of Adolescents and Young Adults with Behaviorally Acquired Human Immunodeficiency Virus. AIDS Patient Care STDS (2017) 0.75

Awareness and perceived fairness of Option B+ in Malawi: A population-level perspective J Int AIDS Soc (2017) 0.75

HIV Prevention Among Transgender Populations: Knowledge Gaps and Evidence for Action. Curr HIV/AIDS Rep (2017) 0.75

Impact of early antiretroviral therapy on the performance of HIV rapid tests and HIV incidence assays. J Acquir Immune Defic Syndr (2017) 0.75

Early initiation of antiretroviral therapy prevents HIV transmission to seronegative sexual partners. Evid Based Med (2016) 0.75

Increased Persistence of Initial Treatment for HIV Infection with Modern Antiretroviral Therapy. J Acquir Immune Defic Syndr (2017) 0.75

A Comparison of Hepatitis B Virus Infection in HIV-infected and HIV-uninfected Participants Enrolled in a Multi-National Clinical Trial: HPTN 052. J Acquir Immune Defic Syndr (2017) 0.75

A Longitudinal Analysis of Treatment Optimism and HIV Acquisition and Transmission Risk Behaviors Among Black Men Who Have Sex with Men in HPTN 061. AIDS Behav (2017) 0.75

Articles cited by this

Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36

Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med (2000) 41.18

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med (2015) 15.06

Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med (2010) 12.08

A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med (2015) 5.30

Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med (2013) 4.26

Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis (2011) 3.78

Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis (2014) 3.69

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. JAMA (2016) 3.64

Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS (2013) 3.30

Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med (2011) 2.76

Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here? Lancet (2013) 2.31

Is transmission of HIV-1 in non-viraemic serodiscordant couples possible? Antivir Ther (2008) 2.21

HPTN 071 (PopART): rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment - a study protocol for a cluster randomised trial. Trials (2014) 1.94

HPTN 071 (PopART): a cluster-randomized trial of the population impact of an HIV combination prevention intervention including universal testing and treatment: mathematical model. PLoS One (2014) 1.66

Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev (2013) 1.56

HIV treatment as prevention: considerations in the design, conduct, and analysis of cluster randomized controlled trials of combination HIV prevention. PLoS Med (2012) 1.45

Statistical considerations for the HPTN 052 Study to evaluate the effectiveness of early versus delayed antiretroviral strategies to prevent the sexual transmission of HIV-1 in serodiscordant couples. Contemp Clin Trials (2012) 1.33

Scale-up of Routine Viral Load Testing in Resource-Poor Settings: Current and Future Implementation Challenges. Clin Infect Dis (2016) 1.25

HIV prevention: great achievements, more challenges ahead. J Acquir Immune Defic Syndr (2013) 1.11

Establishing HIV treatment as prevention in the HIV Prevention Trials Network 052 randomized trial: an ethical odyssey. Clin Trials (2012) 1.11

HIV-1 transmission during early antiretroviral therapy: evaluation of two HIV-1 transmission events in the HPTN 052 prevention study. PLoS One (2013) 1.04

Advances in HIV prevention for serodiscordant couples. Curr HIV/AIDS Rep (2014) 1.02

HIV transmission hunting--the chase for low risk events. Antivir Ther (2008) 0.92